drugset / Trial / NCT02540161
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified. This is a phase 2 study that will accrue patients with WHO grade IV recurrent malignant glioma (glioblastoma or gliosarcoma) in two cohorts to assess the efficacy of Sym004.
Timeline
- Start
- 2016-02-01
- Primary completion
- 2019-07-10
- Completion
- 2020-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sym004 | Monoclonal antibody | 18 mg/kg | Intravenous |
| Subject | Sym004 | Monoclonal antibody | 24 mg/kg | Intravenous |